AI to screen 3,000 men for hidden cancers in beijing pilot

NCT ID NCT07319923

Recruiting now Knowledge-focused Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to build and test an AI-based early warning system to screen men aged 50 and older for prostate and bladder cancer. Researchers will enroll 3,000 male residents of Beijing, measuring PSA levels and using AI to flag high-risk individuals. No drugs or devices are given—the goal is to see if a coordinated screening pathway from community clinics to hospitals can catch cancers earlier and improve follow-up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could create a practical, AI-driven screening pathway that catches prostate and bladder cancers earlier in community settings, potentially reducing deaths.
What could go wrong: This is an observational study—no treatment is tested. The AI system may not improve detection rates or be scalable to other populations. Results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COMMUNITY-BASED SCREENING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COMMUNITY-BASED SCREENING PROSTATE CANCER

Contacts and locations

Locations

Department of Urology, Peking University First Hospital, Beijing, 100034
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.